ATE359826T1 - Vorbeugung der kronischen transplantat-abstossung durch eine kombination von immuntoxinen und kostimulationblocker - Google Patents
Vorbeugung der kronischen transplantat-abstossung durch eine kombination von immuntoxinen und kostimulationblockerInfo
- Publication number
- ATE359826T1 ATE359826T1 AT00904230T AT00904230T ATE359826T1 AT E359826 T1 ATE359826 T1 AT E359826T1 AT 00904230 T AT00904230 T AT 00904230T AT 00904230 T AT00904230 T AT 00904230T AT E359826 T1 ATE359826 T1 AT E359826T1
- Authority
- AT
- Austria
- Prior art keywords
- recipient
- transplant
- administering
- combination
- cronic
- Prior art date
Links
- 229940051026 immunotoxin Drugs 0.000 title abstract 3
- 239000002596 immunotoxin Substances 0.000 title abstract 3
- 231100000608 immunotoxin Toxicity 0.000 title abstract 3
- 206010052779 Transplant rejections Diseases 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 238000000034 method Methods 0.000 abstract 4
- 230000001154 acute effect Effects 0.000 abstract 3
- 230000001684 chronic effect Effects 0.000 abstract 3
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 2
- 230000004940 costimulation Effects 0.000 abstract 2
- 230000002637 immunotoxin Effects 0.000 abstract 2
- 230000004044 response Effects 0.000 abstract 2
- 230000005875 antibody response Effects 0.000 abstract 1
- 230000003111 delayed effect Effects 0.000 abstract 1
- 229940125721 immunosuppressive agent Drugs 0.000 abstract 1
- 239000003018 immunosuppressive agent Substances 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Transplantation (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11525299P | 1999-01-08 | 1999-01-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE359826T1 true ATE359826T1 (de) | 2007-05-15 |
Family
ID=22360179
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00904230T ATE359826T1 (de) | 1999-01-08 | 2000-01-06 | Vorbeugung der kronischen transplantat-abstossung durch eine kombination von immuntoxinen und kostimulationblocker |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1144010B1 (de) |
| AT (1) | ATE359826T1 (de) |
| AU (1) | AU768547B2 (de) |
| CA (1) | CA2358435A1 (de) |
| DE (1) | DE60034428T2 (de) |
| DK (1) | DK1144010T3 (de) |
| ES (1) | ES2286006T3 (de) |
| PT (1) | PT1144010E (de) |
| WO (1) | WO2000040270A2 (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7288254B2 (en) | 1995-10-30 | 2007-10-30 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services, Nih | Use of immunotoxins to induce immune tolerance to pancreatic islet transplantation |
| US7517527B2 (en) | 1995-10-30 | 2009-04-14 | The United States Of America As Represented By The Department Of Health And Human Services | Immunotoxin with in vivo T cell suppressant activity and methods of use |
| US7696338B2 (en) | 1995-10-30 | 2010-04-13 | The United States Of America As Represented By The Department Of Health And Human Services | Immunotoxin fusion proteins and means for expression thereof |
| CA2284079C (en) | 1997-03-05 | 2009-05-12 | David M. Neville | Immunotoxins and methods of inducing immune tolerance |
| GB0815788D0 (en) * | 2008-08-29 | 2008-10-08 | Isis Innovation | Therapeutic antibodies |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2191733A1 (en) * | 1994-06-07 | 1995-12-21 | Daniel A. Vallera | Methods for inhibiting antigen specific t cell responses |
| WO1996032137A2 (en) * | 1995-04-14 | 1996-10-17 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Methods of inducing immune tolerance using immunotoxins |
| CA2284079C (en) * | 1997-03-05 | 2009-05-12 | David M. Neville | Immunotoxins and methods of inducing immune tolerance |
| SK156099A3 (en) * | 1997-05-17 | 2000-06-12 | Biogen Inc | Use of a cd40:cd154 binding interruptor to prevent counter adaptive immune responses, particularly graft rejection |
| EP1009432A4 (de) * | 1997-06-11 | 2004-07-07 | Us Navy | Zusammensetzungen und methoden zur hemmung von transplantatabstossung und anderen gegen die annahme gerichteten von t-lymphozyten vermittelten immunantworten |
| WO1999053954A1 (en) * | 1998-04-22 | 1999-10-28 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Use of immunotoxins to induce immune tolerance to pancreatic islet transplantation |
-
2000
- 2000-01-06 ES ES00904230T patent/ES2286006T3/es not_active Expired - Lifetime
- 2000-01-06 CA CA002358435A patent/CA2358435A1/en not_active Abandoned
- 2000-01-06 DK DK00904230T patent/DK1144010T3/da active
- 2000-01-06 AU AU26017/00A patent/AU768547B2/en not_active Ceased
- 2000-01-06 WO PCT/US2000/000284 patent/WO2000040270A2/en not_active Ceased
- 2000-01-06 DE DE60034428T patent/DE60034428T2/de not_active Expired - Fee Related
- 2000-01-06 AT AT00904230T patent/ATE359826T1/de not_active IP Right Cessation
- 2000-01-06 EP EP00904230A patent/EP1144010B1/de not_active Expired - Lifetime
- 2000-01-06 PT PT00904230T patent/PT1144010E/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000040270A2 (en) | 2000-07-13 |
| DE60034428D1 (de) | 2007-05-31 |
| ES2286006T3 (es) | 2007-12-01 |
| WO2000040270A3 (en) | 2001-10-18 |
| PT1144010E (pt) | 2007-07-20 |
| AU2601700A (en) | 2000-07-24 |
| EP1144010A2 (de) | 2001-10-17 |
| DE60034428T2 (de) | 2008-01-03 |
| EP1144010B1 (de) | 2007-04-18 |
| EP1144010A3 (de) | 2002-02-06 |
| AU768547B2 (en) | 2003-12-18 |
| CA2358435A1 (en) | 2000-07-13 |
| DK1144010T3 (da) | 2007-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE163191T1 (de) | Silberkorrosionsschutzmittel i | |
| FR2869229A1 (fr) | Utilisation d'un inducteur des ugt par voie topique | |
| WO2002085387A3 (en) | A medicament or a dressing containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent ans their use in the treatment of inflammatory skin conditions | |
| DK0881901T3 (da) | Kombination af aktive stoffer, der indeholder clopidogrel og et antithrombotisk middel | |
| ATE218353T1 (de) | Antimikrobielles mittel bestehend aus gläser mit kontrollierter abgabe | |
| MA27177A1 (fr) | Synthese controlee de ziprasidone et compositions en contenant. | |
| MY122621A (en) | Compositions containing a high percent saturation concentration of antibacterial agent | |
| DK0736084T3 (da) | Enzympræparat indeholdende et middel til beskyttelse af sølv mod korrosion | |
| DE60041753D1 (de) | Arzneimittel zur behandlung von c. pneumoniae infektionen | |
| EP1011331A4 (de) | Hemmung von durch sulfat-reduzierende bakterien vermitteltem abbau durch verwendung von bakterien, die antimirkobrobielle stoffe ausscheiden | |
| DE59505104D1 (de) | Konservierungsmittel | |
| ATE424893T1 (de) | Behandlung und vorbeugung von insulin- produzierende zelltransplantatabstossung | |
| DE50103006D1 (de) | Mikrobizid wirksame tenside | |
| DE60034428D1 (de) | Vorbeugung der kronischen transplantat-abstossung durch eine kombination von immuntoxinen und kostimulationblocker | |
| FI955261A0 (fi) | P-selektiinin vasta-aineita ja niiden käyttö | |
| GT200000150A (es) | Empleo de compuestos polihidroxilados y de agentes de deslizamiento de cadenas. | |
| WO2002024727A3 (en) | New inhibitors of iapp fibril formation and uses thereof | |
| FR2710844B1 (fr) | Composition pour le traitement ou la prévention de l'herpès. | |
| BR9914722A (pt) | Derivados de anticonvulsivo úteis no tratamento de dependência, vìcio e abuso do álcool | |
| IL126651A0 (en) | Acyl urea compounds for the treatment of coccidioidomycosis in warm-blooded animals | |
| GB9802542D0 (en) | New use | |
| TW366366B (en) | An alloy, in particular for use in the manufacture of frames for eyeglasses, jewelry and the like | |
| FR2818134B1 (fr) | Composition, notamment cosmetique, renfermant la 7-hydroxy dhea et/ou la 7-ceto dhea et au moins un agent antimicrobien | |
| DK0883408T3 (da) | Ophthalmologisk anvendelig sammentsætning, produkter indeholdende sammensætningen og fremgangsmåde til desinfektion og/eller rensning af kontaktlinser | |
| CA2162149A1 (en) | Antibodies to p-selectin and their uses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1144010 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |